Loading
Targeted drugs briefly make cancer cells easier for the immune system to spot. Giving immunotherapy exactly in that window, rather than at the same time, may work better.
MAPK and CDK4/6 inhibition transiently increase MHC class I expression, antigen presentation and interferon signalling, then this fades as resistance develops. Concurrent combinations have often been toxic and no more effective. Mass spectrometry immunopeptidomics and MHC imaging could define the window in patients, and immunotherapy could be scheduled to coincide with peak presentation rather than dosed continuously alongside.
Shares Too many combinations to test, Acquired resistance to every therapy, RAS / RAF / MEK / ERK (MAPK), Immune checkpoint inhibitors.
Shares CDK4/6 inhibitors, Melanoma, HR-positive / HER2-negative breast cancer.
Shares Too many combinations to test, CDK4/6 inhibitors, Acquired resistance to every therapy.
Shares Too many combinations to test, Immune checkpoint inhibitors.
Shares Proteomics & phosphoproteomics, Acquired resistance to every therapy.
Shares No one can predict who responds to immunotherapy, Melanoma, Immune checkpoint inhibitors.
Shares No one can predict who responds to immunotherapy, PD-1 / PD-L1 immune checkpoint & T-cell activation, Melanoma, Immune checkpoint inhibitors.
Shares No one can predict who responds to immunotherapy, Melanoma, Immune checkpoint inhibitors.